No Data
Jiangxi Fushine Pharmaceutical (300497.SZ) plans to establish two joint ventures to promote the development of the synthetic biology sector.
Jiangxi Fushine Pharmaceutical (300497.SZ) announced that the company will hold the second meeting of the fourth board of directors on December 1, 2024...
Express News | Jiangxi Fushine Pharmaceutical: Intends to establish two joint ventures in cooperation with Yihai Kerry Arowana Holdings.
Express News | Jiangxi Fushine Pharmaceutical: Appoints Ke Dan as Vice President
Express News | Summary of shareholding reductions by listed companies on November 14.
Express News | Jiangxi Fushine Pharmaceutical: Certain shareholders plan to reduce their shareholding by no more than 0.82% of the company's shares.
jiangxi fushine pharmaceutical: Currently, the company has an annual production capacity of 8,000 tons of VC products.
On November 14th, Richluck Pharmaceutical stated on the investor interaction platform that the company currently has a production capacity of 8,000 tons/year of VC products and has planned to increase the production capacity of VC products to 0.02 million tons/year. According to statistics, in 2023, the company's VC product shipment volume has ranked among the top in the industry.
No Data
No Data